A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

NCT04511975 ↗

Phase 1 Suspended 32 enrolled Innovent Biologics (Suzhou) Co. Ltd.

NaSequentialOpen-labelTreatment

Summary

This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS patients.

Timeline

Start: 2020-08-24
Primary completion: 2021-10-31
Completion: 2022-04-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	100 mg	Subcutaneous
Subject	IBI188	Monoclonal antibody	100 mg/ml	Intravenous

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Summary

Timeline

Drugs

Indications